The Microbiota and infectious diarrhea;Le microbiote dans les diarrhées infectieuses.

Gastroenterologie Clinique et Biologique

Volumn 34, Issue SUPPL. 1, 2010, Pages

  Surawicz, C M ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINDAMYCIN; DEFENSIN; LINCOMYCIN; METRONIDAZOLE; PENICILLIN DERIVATIVE; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; RNA 16S; SHORT CHAIN FATTY ACID; STREPTOMYCIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC ASSOCIATED DIARRHEA; ANTIBIOTIC ASSOCIATED HEMORRHAGIC COLITIS; ARTICLE; BACILLUS; BACILLUS CLAUSII; BIFIDOBACTERIACEAE; BILE; CLINICAL ASSESSMENT; CLOSTRIDIUM BUTYRICUM; CLOSTRIDIUM DIFFICILE; COLITIS; COLON RESECTION; DIARRHEA; ENTERITIS; ENTEROCOCCUS FAECIUM; FATTY ACID METABOLISM; FECES MICROFLORA; HAMSTER; HUMAN; IMMUNE RESPONSE; INFECTION RISK; INFECTION SENSITIVITY; INFECTIOUS DIARRHEA; INTESTINE INFECTION; INTESTINE MOTILITY; KLEBSIELLA OXYTOCA; LACTOBACILLUS; LACTOBACILLUS ACIDOPHILUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PANETH CELL; PATHOPHYSIOLOGY; PEPTIC ULCER; PERISTALSIS; PSEUDOMEMBRANOUS COLITIS; RECURRENT INFECTION; SACCHAROMYCES BOULARDII; SALMONELLA; SHIGELLA; STOMACH ACID; STOMACH PROTECTION; CLOSTRIDIUM INFECTION; DRUG COMBINATION; DRUG EFFECT; METAGENOME; MICROBIOLOGY; SACCHAROMYCES; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DIARRHEA; DRUG THERAPY, COMBINATION; HUMANS; METAGENOME; PROBIOTICS; SACCHAROMYCES; TREATMENT OUTCOME;

EID: 77957355199     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0399-8320(10)70018-X     Document Type: Article

References (61)

1. Tlaskalová-Hogenová H., Stepánková R., Hudcovic T., Tucková L., Cukrowska B., Lodinová-Zádníková R., et al. Commensal bacteria (normal microflora), mucosal immunity and chronic inflammatory and autoimmune diseases. Immunol Lett 2004, 93:97-108.
2. Navaneethan U., Giannella R.A. Mechanisms of infectious diarrhea. Nat Clin Pract Gastroenterol Hepatol 2008, 5:637-647.
3. Jiang Z.D., Okhuysen P.C., Guo D.C., He R., King T.M., DuPont H.L., et al. Genetic susceptibility in enteroaggregative Escherichia coli diarrhea: polymorphism in the interleukin-8 promotor region. J Infect Dis 2003, 188:506-511.
4. Evans C.A., Gilman R.H., Rabbani G.H., Salazar G., Ali A. Gastric acid secretion and enteric infection in Bangladesh. Trans R Soc Trop Med Hyg 1997, 91:681-685.
5. Leonard J., Marshall J.K., Moayyedi P. Systematic review of the risk of enteric infections in patients taking acid suppression. Am J Gastroenterol 2007, 102:2047-2056.
6. DuPont H.L., Hornick R.B. Adverse effects of lomotil therapy in shigellosis. JAMA 1973, 226:1525-1528.
7. Surawicz C.M. Antibiotic-associated diarrhea and pseudomembranous colitis: are they less common with poorly absorbed antimicrobials?. Chemotherapy 2005, 51:81-89.
8. Sullivan A., Edlund C., Nord C.E. Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect Dis 2001, 1:101-114.
9. Freter R. The fatal enteric cholera infection in the guinea pig, achieved by inhibition of normal enteric flora. J Infect Dis 1955, 97:57-65.
10. Freter R. In vivo and in vitro antagonism of intestinal bacteria against Shigella flexneri. II. The inhibitory mechanism. J Infect Dis 1962, 110:38-46.
11. Bartlett J.G., Onderdonk A.B., Cisneros R.L. Clindamycin-associated colitis in hamsters: protection with vancomycin. Gastroenterology 1977, 73:772-776.
12. Guarner F., Malagelada J.R. Gut flora in health and disease. Lancet 2003, 361:512-519.
13. McFarland L.V. Normal flora: diversity and functions. Microb Ecol Health Dis 2000, 12:193-207.
14. Fons M., Gomez A., Karjalainen T. Mechanisms of colonization resistance of the digestive tract. Microb Ecol Health Dis 2000, 12:240-246.
15. Raqib R., Sarker P., Bergman P., Ara G., Lindh M., Sack D.A., et al. Improved outcome in shigellosis associated with butyrate induction of an endogenous peptide antibiotic. Proc Natl Acad Sci USA 2006, 103:9178-9183.
16. Wilson K.H., Perini F. Role of competition for nutrients in suppression of Clostridium difficile by the colonic microflora. Infect Immun 1988, 56:2610-2614.
17. Ley R.E., Turnbaugh P.J., Klein S., Gordon J.I. Microbial ecology: human gut microbes associated with obesity. Nature 2006, 444:1022-1023.
18. Gibson G.R., Beatty E.R., Wang X., Cummings J.H. Selective stimulation of bifidobacteria in the human colon by oligofructose and inulin. Gastroenterology 1997, 108:975-982.
19. Bernet M.F., Brassart D., Neeser J.R., Servin A.L. Lactobacillus acidophilus LA 1 binds to cultured human intestinal cell lines and inhibits cell attachment and cell invasion by enterovirulent bacteria. Gut 1994, 35:483-489.
20. Hooper L.V., Xu J., Falk P.G., Midtvedt T., Gordon J.I. A molecular sensor that allows a gut commensal to control its nutrient foundation in a competitive ecosystem. Proc Natl Acad Sci USA 1999, 96:9833-9838.
21. Stecher B., Robbiani R., Walker A.W., Westendorf A.M., Barthel M., Kremer M., et al. Salmonella enterica serovar typhimurium exploits inflammation to compete with the intestinal microbiota. PLoS Biol 2007, 5:2177-2189.
22. Lupp C., Robertson M.L., Wickham M.E., Sekirov I., Champion O.L., Gaynor E.C., et al. Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of Enterobacteriaceae. Cell Host Microbe 2007, 2:119-129.
23. Balamurugan R., Janardhan H.P., George S., Raghava M.V., Muliyil J., Ramakrishna B.S. Molecular studies of fecal anaerobic commensal bacteria in acute diarrhea in children. J Pediatr Gastroenterol Nutr 2008, 46:514-519.
24. Bohnhoff M., Miller C.P. Enhanced susceptibility to Salmonella infection in streptomycin-treated mice. J Infect Dis 1962, 111:117-127.
25. Donskey C.J., Hujer A.M., Das S.M., Pultz N.J., Bonomo R.A., Rice L.B. Use of denaturing gradient gel electrophoresis for analysis of the stool microbiota of hospitalized patients. J Microbiol Methods 2003, 54:249-256.
26. Yap I.K., Li J.V., Saric J., Martin F.P., Davies H., Wang Y., et al. Metabonomic and microbiological analysis of the dynamic effect of vancomycin-induced gut microbiota modification in the mouse. J Proteome Res 2008, 7:3718-3728.
27. De La Cochetière M.F., Durand T., Lepage P., Bourreille A., Galmiche J.P., Doré J. Resilience of the dominant human fecal microbiota upon short-course antibiotic challenge. J Clin Microbiol 2005, 43:5588-5592.
28. Jernberg C., Löfmark S., Edlund C., Jansson J.K. Long-term ecological impacts of antibiotic administration on the human intestinal microbiota. ISME J 2007, 1:56-66.
29. Young V.B., Schmidt T.M. Antibiotic-associated diarrhea accompanied by large-scale alterations in the composition of the fecal microbiota. J Clin Microbiol 2004, 42:1203-1206.
30. Surawicz C.M. Role of probiotics in antibiotic-associated diarrhea. Clostridium difficile-associated diarrhea, and recurrent Clostridium difficile-associated diarrhea. J Clin Gastroenterol 2008, 42:S64-S70.
31. Beniwal R.S., Arena V.C., Thomas L., Narla S., Imperiale T.F., Chaudhry R.A., et al. A randomized trial of yogurt for prevention of antibiotic-associated diarrhea. Dig Dis Sci 2003, 48:2077-2082.
32. Conway S., Hart A., Clark A., Harvey I. Does eating yogurt prevent antibiotic-associated diarrhoea? A placebo-controlled randomised controlled trial in general practice. Br J Gen Pract 2007, 57:953-959.
33. Lewis S., Burmeister S., Cohen S., Brazier J., Awasthi A. Failure of dietary oligofructose to prevent antibiotic-associated diarrhoea. Aliment Pharmacol Ther 2005, 21:469-477.
34. Muto C.A., Pokrywka M., Shutt K., Mendelsohn A.B., Nouri K., Posey K., et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005, 26:273-280.
35. Pépin J., Valiquette L., Alary M.E., Villemure P., Pelletier A., Forget K., et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004, 171:466-472.
36. Bassaris H.P., Lianou P.E., Legakis N.J., Papavassiliou J.T. Interaction between Clostridium difficile and polymorphonuclear leucocytes from the elderly and post-operative cancer patients: phagocytosis and bactericidal function. Med Microbiol Immunol 1984, 173:49-55.
37. Enck P., Zimmermann K., Rusch K., Schwiertz A., Klosterhalfen S., Frick J.S. The effects of ageing on the colonic bacterial microflora in adults. Z Gastroenterol 2009, 47:653-658.
38. Ananthakrishnan A.N., McGinley E.L., Binion D.G. Excess hospitalization burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut 2008, 57:205-210.
39. Issa M., Vijayapal A., Graham M.B., Beaulieu D.B., Otterson M.F., Lundeen S., et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol 2007, 5:345-351.
40. Rodemann J.F., Dubberke E.R., Reske K.A., Seo da H., Stone C.D. Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol 2007, 5:339-344.
41. Bajaj J.S., Ananthakrishnan A.N., Hafeezullah M., Zadvornova Y., Dye A., McGinley E.L., et al. Clostridium difficile is associated with poor outcomes in patients with cirrhosis: a national and tertiary care center perspective. Am J Gastroenterol 2010, 105:106-113.
42. Dial S., Delaney J.A., Schneider V., Suissa S. Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy. CMAJ 2006, 175:745-748.
43. Lowe D.O., Mamdani M.M., Kopp A., Low D.E., Juurlink D.N. Proton pump inhibitors and hospitalization for Clostridium difficile-associated disease: a population-based study. Clin Infect Dis 2006, 43:1272-1276.
44. Högenauer C., Langner C., Beubler E., Lippe I.T., Schicho R., Gorkiewicz G., et al. Klebsiella oxytoca as a causative organism of antibiotic-associated hemorrhagic colitis. N Engl J Med 2006, 355:2418-2426.
45. Sweetser S., Schroeder K.W., Pardi D.S. Pseudomembranous colitis secondary to Klebsiella oxytoca. Am J Gastroenterol 2009, 104:2366-2368.
46. Boyce J.M., Havill N.L. Nosocomial antibiotic-associated diarrhea associated with enterotoxin-producing strains of methicillinresistant Staphylococcus aureus. Am J Gastroenterol 2005, 100:1828-1834.
47. Chang J.Y., Antonopoulos D.A., Kalra A., Tonelli A., Khalife W.T., Schmidt T.M., et al. Decreased diversity of the fecal Microbiota in recurrent Clostridium difficile-associated diarrhea. J Infect Dis 2008, 197:435-438.
48. Kyne L., Warny M., Qamar A., Kelly C.P. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001, 357:189-193.
49. McFarland L.V., Elmer G., Surawicz C.M. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002, 97:1769-1775.
50. McFarland L.V., Surawicz C.M., Greenberg R.N., Fekety R., Elmer G.W., Moyer K.A., et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994, 271:1913-1918.
51. Surawicz C.M., McFarland L.V., Greenberg R.N., Rubin M., Fekety R., Mulligan M.E., et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 2000, 31:1012-1017.
52. Wullt M., Hagslätt M.L., Odenholt I. Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trial. Scand J Infect Dis 2003, 35:365-367.
53. Pochapin M. The effect of probiotics on Clostridium difficile diarrhea. Am J Gastroenterol 2000, 95:S11-S13.
54. Lawrence S.J., Korzenik J.R., Mundy L.M. Probiotics for recurrent Clostridium difficile disease. J Med Microbiol 2005, 54:905-906.
55. Lewis S., Burmeister S., Brazier J. Effect of the prebiotic oligofructose on relapse of Clostridium difficile-associated diarrhea: a randomized, controlled study. Clin Gastroenterol Hepatol 2005, 3:442-448.
56. Bowden T.A., Mansberger A.R., Lykins L.E. Pseudomembraneous enterocolitis: mechanism for restoring floral homeostasis. Am Surg 1981, 47:178-183.
57. Schwan A., Sjölin S., Trottestam U., Aronsson B. Relapsing Clostridium difficile enterocolitis cured by rectal infusion of normal faeces. Scand J Infect Dis 1984, 16:211-215.
58. Tvede M., Rask-Madsen J. Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients. Lancet 1989, 1:1156-1160.
59. Persky S., Brandt L.J. Treatment of recurrent Clostridium difficile-associated diarrhea by administration of donated stool directly through a colonoscope. Am J Gastroenterol 2000, 95:3283-3285.
60. Aas J., Gessert C.E., Bakken J.S. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis 2003, 36:580-585.
61. Macconnachie A.A., Fox R., Kennedy D.R., Seaton R.A. Faecal transplant for recurrent Clostridium difficile-associated diarrhoea: a UK case series. QJM 2009, 102:781-784.